N@N

LONDON, ONTARIO--(Marketwire - Sept. 30, 2009) - Sernova Corp. (TSX VENTURE:SVA) is pleased to announce that the company has accepted an invitation to present scientific results from its islet transplantation studies using its Cell Pouch System(TM) at a joint conference of the International Pancreas and Islet Transplant Association and the International Xenotransplantation Association to be held in Venice, Italy from October 12 – 16.

Dr. David White, Chairman of Sernova's Scientific Advisory Board, said "We are very pleased to receive the recognition afforded by this important invitation to present our research to the international scientific community. This international conference is an excellent opportunity to explain the virtues of the Sernova Cell Pouch System(TM), which provides a biocompatible chamber which eliminates many of the current issues with the standard of treatment related to injection of cells into the body"

The conference will bring together the most eminent scientists and clinicians in the cell transplantation field from around the world. Sernova will be presenting seven abstracts, three of which will be highlighted in podium presentations, creating an excellent venue to discuss the novel and important aspects of Sernova's revolutionary approach to cellular therapies, such as islet cell transplantation for diabetes.

Sernova will provide additional information on presentation times as well as study results as the conference proceeds.

About Sernova

Sernova Corp. is a Canadian-based, health-sciences company focused on commercializing medical technologies. Sernova is currently developing a platform technology for a number of serious disease indications, starting with a novel treatment for insulin-dependent diabetes, using the novel Cell Pouch System(TM) and its patented Sertolin(TM) cell technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out of every 8 dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $15 billion annually and growing.

This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

THE TSX VENTURE EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE.